We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+47.82%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$808M
AUM Growth
+$260M
Cap. Flow
-$29.2M
Cap. Flow %
-3.62%
Top 10 Hldgs %
40.15%
Holding
122
New
39
Increased
28
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$17.4M
2
VERA icon
Vera Therapeutics
VERA
+$16.7M
3
ONC
BeOne Medicines Ltd
ONC
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$11.4M
5
KURA icon
Kura Oncology
KURA
+$10.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$41.6M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.8M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$18.9M
4
LIAN
LianBio American Depositary Shares
LIAN
+$16.9M
5
VKTX icon
Viking Therapeutics
VKTX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 70.51%
2 Miscellaneous 29.3%
3 Financials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
CALL
Ironwood Pharmaceuticals
IRWD
$704M
$8.97M 1.11%
+1,029,500
New +$12.5M
CMPS
27
Compass Pathways
CMPS
$1.84B
$8.55M 1.06%
1,027,868
+477,868
+87% +$4.82M
NARI
28
DELISTED
Inari Medical, Inc. Common Stock
NARI
$8.4M 1.04%
175,000
+155,000
+775% +$8.28M
ESTA icon
29
Establishment Labs
ESTA
$2.21B
$8.38M 1.04%
164,589
-63,688
-28% -$2.56M
GERN icon
30
Geron
GERN
$1.01B
$8.25M 1.02%
+2,500,000
New +$5.6M
MORF
31
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.92M 0.98%
225,000
+182,330
+427% +$6.11M
BBIO icon
32
CALL
BridgeBio Pharma
BBIO
$14.6B
$7.73M 0.96%
+250,000
New +$8.5M
NAMS icon
33
NewAmsterdam Pharma
NAMS
$3.04B
$6.77M 0.84%
286,200
+161,200
+129% +$3.27M
ELEV
34
DELISTED
Elevation Oncology
ELEV
$6.51M 0.81%
+1,268,825
New +$4.11M
GRTS
35
PUT
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$6.14M 0.76%
+2,390,600
New +$5.84M
CATX icon
36
Perspective Therapeutics
CATX
$357M
$6.07M 0.75%
+510,000
New +$4.35M
ALNY icon
37
CALL
Alnylam Pharmaceuticals
ALNY
$35.6B
$5.98M 0.74%
40,000
+10,000
+33% +$1.67M
ABSI icon
38
Absci
ABSI
$1.51B
$5.82M 0.72%
+1,025,000
New +$4.62M
SVRA icon
39
Savara
SVRA
$1.1B
$5.73M 0.71%
1,150,000
– –
CYTK icon
40
Cytokinetics
CYTK
$10.1B
$5.61M 0.69%
80,000
-80,000
-50% -$6.19M
PCVX icon
41
Vaxcyte
PCVX
$9.1B
$5.46M 0.68%
80,000
+55,000
+220% +$3.81M
ROIV icon
42
Roivant Sciences
ROIV
$25.2B
$5.27M 0.65%
500,000
– –
FULC icon
43
Fulcrum Therapeutics
FULC
$294M
$5.2M 0.64%
550,339
+425,339
+340% +$3.8M
RAPT
44
PUT
DELISTED
RAPT Therapeutics
RAPT
$5.18M 0.64%
+72,138
New +$10M
GH icon
45
CALL
Guardant Health
GH
$21.7B
$5.16M 0.64%
+250,000
New +$5.36M
SWTX
46
DELISTED
SpringWorks Therapeutics
SWTX
$4.92M 0.61%
100,000
– –
KRYS icon
47
Krystal Biotech
KRYS
$10.6B
$4.76M 0.59%
26,746
+1,746
+7% +$243K
IMVT icon
48
CALL
Immunovant
IMVT
$8.11B
$4.67M 0.58%
+144,400
New +$5.27M
MRSN
49
DELISTED
Mersana Therapeutics
MRSN
$4.48M 0.55%
40,000
– –
CRSP icon
50
CALL
CRISPR Therapeutics
CRSP
$5.39B
$4.43M 0.55%
+65,000
New +$4.65M
1
2
3 4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Affinity Asset Advisors held 122 positions worth $808M, up 48% from $548M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Affinity Asset Advisors withdrew a net $29.2M in Q1 2024, closing 27 positions and reducing 16 holdings. Its most notable exit was Immunogen Inc, an estimated $41.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Affinity Asset Advisors opened a new position in Vera Therapeutics worth $20.3M.

  • Affinity Asset Advisors's largest Q1 2024 buy was Vera Therapeutics: 470,000 shares worth $20.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q1 2024, an estimated $17.4M increase.
  • Affinity Asset Advisors's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $18.9M.
  • Affinity Asset Advisors fully exited Immunogen Inc in Q1 2024, selling an estimated $41.6M.
  • Affinity Asset Advisors's ten largest holdings make up 40% of its $808M portfolio in Q1 2024.
  • Affinity Asset Advisors opened 39 new positions and closed 27 in Q1 2024.
  • Affinity Asset Advisors's portfolio value rose 48% quarter-over-quarter to $808M.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.